Biljana Naumovic is the Worldwide Vice President, Global Commercial Strategy, Oncology for the Janssen Pharmaceutical Companies of Johnson & Johnson. Working in collaboration with Janssen Research & Development, she is responsible for the development of breakthrough commercial strategies to deliver a sustainable and differentiated oncology pipeline. In this role, she oversees multiple functions that support the Global Oncology business such as Strategic Marketing, Market Access, Medical Affairs, and Portfolio. Prior to this appointment, Biljana held the position of Managing Director, Janssen Australia & New Zealand (Janssen-Cilag Pty Ltd.) where she oversaw a cultural transformation and reorganization of the business, culminating in double digit growth in 2021. Biljana first joined Janssen in 2019 as Vice President, Oncology for Europe, the Middle East and Africa, where she was responsible for creating and delivering the commercial strategy across the solid tumor portfolio and pipeline spanning prostate cancer, bladder cancer, and lung cancer, and multiple novel tumor pathways. Before joining Janssen, Biljana held a number of senior positions at AstraZeneca, most recently VP of Commercial for Europe. Biljana is a physician by training and graduated from the Belgrade University Medical School. Biljana also holds an executive education degree from the London Business School.